IMTXW
immatics biotechnologies GmbH [IMTXW] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
IMTXW Stock Summary
Top 10 Correlated ETFs
IMTXW
Top 10 Correlated Stocks
IMTXW
In the News
IMTXW Financial details
Company Rating
Sell
Market Cap
1.05B
Income
-92.37M
Revenue
54M
Book val./share
2.66
Cash/share
5.03
Dividend
-
Dividend %
-
Employees
432
Optionable
No
Shortable
Yes
Earnings
08 Jun 2020
P/E
0
Forward P/E
-
PEG
-
P/S
11.8
P/B
-
P/C
0.48
P/FCF
-7.67
Quick Ratio
3.03
Current Ratio
3.18
Debt / Equity
0.07
LT Debt / Equity
0.06
-
-
EPS (TTM)
-1.15
EPS next Y
-
EPS next Q
-
EPS this Y
-318.18%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
19.14%
Revenue last 5Y
23.96%
Revenue Q/Q
168.66%
EPS Q/Q
-3.13%
-
-
-
-
SMA20
-25%
SMA50
-
SMA100
50%
Inst Own
0%
Inst Trans
0%
ROA
-19%
ROE
-38%
ROC
-0.23%
Gross Margin
100%
Oper. Margin
-98%
Profit Margin
-111%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
2.7-2.7
52W High
+19.5%
52W Low
+19.5%
RSI
39
Rel Volume
-
Avg Volume
-
Volume
530
Perf Week
-4.78%
Perf Month
-39.49%
Perf Quarter
-
Perf Half Y
-14.95%
-
-
-
-
Beta
0.676
-
-
Volatility
0.18%, 0.51%
Prev Close
0%
Price
2.39
Change
-0.42%
IMTXW Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-12-31
| Metric | History | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0.29 | 0.65 | 0.55 | 2.57 | 0.67 | |
| Net income per share | -0.5 | -4.78 | -1.51 | 0.56 | -1.2 | |
| Operating cash flow per share | 1.13 | -1.78 | -1.3 | 1.49 | 0.23 | |
| Free cash flow per share | 1.09 | -1.94 | -1.39 | 1.4 | -0.16 | |
| Cash per share | 1.9 | 4.83 | 2.31 | 5.39 | 5.29 | |
| Book value per share | -0.67 | 2.17 | 0.38 | 3.17 | 2.79 | |
| Tangible book value per share | -0.67 | 2.15 | 0.36 | 3.15 | 2.78 | |
| Share holders equity per share | -0.67 | 2.17 | 0.38 | 3.17 | 2.79 | |
| Interest debt per share | 0.05 | 0.13 | 0.18 | 0.34 | 0.2 | |
| Market cap | 581.3M | 423.67M | 746.62M | 548.78M | 767.33M | |
| Enterprise value | 481.18M | 222.33M | 623.48M | 414.83M | 564.26M | |
| P/E ratio | -18.31 | -1.85 | -7.85 | 14.63 | -7.91 | |
| Price to sales ratio | 31.51 | 13.56 | 21.48 | 3.18 | 14.21 | |
| POCF ratio | 8.19 | -4.95 | -9.13 | 5.48 | 42.1 | |
| PFCF ratio | 8.46 | -4.55 | -8.54 | 5.84 | -60.28 | |
| P/B Ratio | -13.89 | 4.06 | 31.03 | 2.57 | 3.41 | |
| PTB ratio | -13.89 | 4.06 | 31.03 | 2.57 | 3.41 | |
| EV to sales | 26.08 | 7.11 | 17.94 | 2.4 | 10.45 | |
| Enterprise value over EBITDA | -16.96 | -3.45 | -8.27 | 8.95 | -7 | |
| EV to operating cash flow | 6.78 | -2.6 | -7.62 | 4.14 | 30.96 | |
| EV to free cash flow | 7 | -2.39 | -7.13 | 4.42 | -44.33 | |
| Earnings yield | -0.05 | -0.54 | -0.13 | 0.07 | -0.13 | |
| Free cash flow yield | 0.12 | -0.22 | -0.12 | 0.17 | -0.02 | |
| Debt to equity | -0.08 | 0.06 | 0.41 | 0.07 | 0.07 | |
| Debt to assets | 0.02 | 0.02 | 0.06 | 0.04 | 0.03 | |
| Net debt to EBITDA | 3.53 | 3.12 | 1.63 | -2.89 | 2.52 | |
| Current ratio | 1.79 | 3.94 | 1.6 | 3.54 | 2.87 | |
| Interest coverage | -194.19 | -241.23 | -50 | 3.62 | -122.41 | |
| Income quality | -2.18 | 0.37 | 0.88 | 2.67 | -0.19 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0.64 | 1.09 | 0.97 | 0.21 | 0.71 | |
| Research and developement to revenue | 2.17 | 2.15 | 2.52 | 0.62 | 2.2 | |
| Intangibles to total assets | 0.01 | 0 | 0.01 | 0 | 0 | |
| Capex to operating cash flow | -0.03 | 0.09 | 0.07 | -0.06 | -1.7 | |
| Capex to revenue | -0.12 | -0.24 | -0.16 | -0.04 | -0.57 | |
| Capex to depreciation | -0.58 | -1.7 | -1.08 | -0.89 | -4.28 | |
| Stock based compensation to revenue | 0.05 | 0.73 | 0.76 | 0.13 | 0.38 | |
| Graham number | 2.75 | 15.28 | 3.61 | 6.31 | 8.7 | |
| ROIC | 0.91 | -0.6 | -2.01 | 0.11 | -0.4 | |
| Return on tangible assets | -0.24 | -0.9 | -0.55 | 0.09 | -0.19 | |
| Graham Net | -0.84 | 1.78 | -0.08 | 2.5 | 1.87 | |
| Working capital | 54.7M | 178.38M | 57.06M | 270.7M | 292.82M | |
| Tangible asset value | -41.84M | 103.34M | 22.75M | 211.53M | 223.56M | |
| Net current asset value | -51.11M | 88.6M | 1.62M | 182.5M | 164.49M | |
| Invested capital | -0.08 | 0.06 | 0.41 | 0.07 | 0.07 | |
| Average receivables | 0 | 2.82M | 1.8M | 896.5K | 3.42M | |
| Average payables | 0 | 3.71M | 7.09M | 12.34M | 10.36M | |
| Average inventory | 0 | 2.27M | 1.65M | 1 | 5.31M | |
| Days sales outstanding | 53.87 | 34.14 | 7.16 | 2.35 | 38.78 | |
| Days payables outstanding | 44.3 | 13.9 | 48.45 | 44.63 | 0 | |
| Days of inventory on hand | 11.25 | 17.97 | 0 | 0 | 0 | |
| Receivables turnover | 6.78 | 10.69 | 50.97 | 155.56 | 9.41 | |
| Payables turnover | 8.24 | 26.27 | 7.53 | 8.18 | 0 | |
| Inventory turnover | 32.44 | 20.31 | 87.57M | 106.78M | 0 | |
| ROE | 0.76 | -2.2 | -3.95 | 0.18 | -0.43 | |
| Capex per share | -0.04 | -0.16 | -0.09 | -0.09 | -0.38 |
Quarterly Fundamentals Overview
Last date of statement is 2023-12-31 for Q4
| Metric | History | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0.55 | 0.13 | 0.29 | 0.07 | 0.19 | |
| Net income per share | -0.19 | -0.2 | -0.32 | -0.32 | -0.31 | |
| Operating cash flow per share | -0.46 | -0.31 | -0.09 | -0.37 | 0.93 | |
| Free cash flow per share | -0.5 | -0.37 | -0.23 | -0.44 | 0.82 | |
| Cash per share | 5.31 | 4.3 | 4.5 | 4.39 | 5.03 | |
| Book value per share | 3.13 | 2.61 | 2.82 | 2.97 | 2.66 | |
| Tangible book value per share | 3.1 | 2.59 | 2.8 | 2.97 | 2.64 | |
| Share holders equity per share | 3.13 | 2.61 | 2.82 | 2.97 | 2.66 | |
| Interest debt per share | 0.32 | 0.2 | 0.22 | 0.2 | 0.18 | |
| Market cap | 556.84M | 485.14M | 820.91M | 921.29M | 806.49M | |
| Enterprise value | 422.88M | 382.19M | 707.33M | 854.31M | 603.42M | |
| P/E ratio | -10.5 | -8.02 | -8.34 | -8.7 | -7.71 | |
| Price to sales ratio | 14.79 | 49.52 | 36.72 | 155.47 | 50.66 | |
| POCF ratio | -17.71 | -20.46 | -124.23 | -30.18 | 10.2 | |
| PFCF ratio | -16.35 | -17.3 | -47.07 | -24.88 | 11.56 | |
| P/B Ratio | 2.61 | 2.42 | 3.76 | 3.72 | 3.58 | |
| PTB ratio | 2.61 | 2.42 | 3.76 | 3.72 | 3.58 | |
| EV to sales | 11.23 | 39.01 | 31.64 | 144.16 | 37.9 | |
| Enterprise value over EBITDA | 40.41 | -17.09 | -72.8 | -31.06 | -28.65 | |
| EV to operating cash flow | -13.45 | -16.12 | -107.04 | -27.99 | 7.63 | |
| EV to free cash flow | -12.42 | -13.63 | -40.56 | -23.07 | 8.65 | |
| Earnings yield | -0.02 | -0.03 | -0.03 | -0.03 | -0.03 | |
| Free cash flow yield | -0.06 | -0.06 | -0.02 | -0.04 | 0.09 | |
| Debt to equity | 0.07 | 0.07 | 0.08 | 0.07 | 0.07 | |
| Debt to assets | 0.04 | 0.04 | 0.04 | 0.04 | 0.03 | |
| Net debt to EBITDA | -12.8 | 4.6 | 11.69 | 2.44 | 9.64 | |
| Current ratio | 3.54 | 3.43 | 2.93 | 3.18 | 2.87 | |
| Interest coverage | 1.16 | -135.54 | -69.49 | -152.6 | -131.35 | |
| Income quality | 2.38 | 1.2 | 0.27 | 1.15 | -3.02 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0.26 | 0.98 | 0.31 | 1.5 | 0.65 | |
| Research and developement to revenue | 0.74 | 2.82 | 1.22 | 5.15 | 2.09 | |
| Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
| Capex to operating cash flow | 0.08 | 0.18 | 1.64 | 0.21 | -0.12 | |
| Capex to revenue | -0.07 | -0.44 | -0.48 | -1.1 | -0.58 | |
| Capex to depreciation | -1.49 | -2.39 | -5.84 | -3.68 | -5.16 | |
| Stock based compensation to revenue | 0.16 | 0.62 | 0.25 | 0.79 | 0.28 | |
| Graham number | 3.7 | 3.4 | 4.5 | 4.61 | 4.3 | |
| ROIC | 0.05 | -0.09 | -0.06 | -0.12 | -0.11 | |
| Return on tangible assets | -0.03 | -0.04 | -0.06 | -0.06 | -0.05 | |
| Graham Net | 2.47 | 2.05 | 2.09 | 2.19 | 1.78 | |
| Working capital | 270.7M | 244.48M | 240.32M | 263.86M | 292.82M | |
| Tangible asset value | 211.53M | 198.52M | 216.56M | 246.12M | 223.56M | |
| Net current asset value | 182.5M | 166.65M | 172.65M | 195.31M | 164.49M | |
| Invested capital | 0.07 | 0.07 | 0.08 | 0.07 | 0.07 | |
| Average receivables | 1.55M | 1.15M | 1.56M | 1.66M | 3.56M | |
| Average payables | 12.94M | 8.88M | 5.09M | 5.81M | 6.91M | |
| Average inventory | 4.46M | 5M | 9.78M | 10.18M | 10.72M | |
| Days sales outstanding | 2.66 | 10.9 | 7.79 | 21.1 | 32.43 | |
| Days payables outstanding | 42.2 | 15.37 | 18.03 | 0 | 0 | |
| Days of inventory on hand | 0 | 32.66 | 31.45 | 0 | 0 | |
| Receivables turnover | 33.89 | 8.26 | 11.55 | 4.27 | 2.78 | |
| Payables turnover | 2.13 | 5.86 | 4.99 | 0 | 0 | |
| Inventory turnover | 27.85M | 2.76 | 2.86 | 0 | 0 | |
| ROE | -0.06 | -0.08 | -0.11 | -0.11 | -0.12 | |
| Capex per share | -0.04 | -0.06 | -0.14 | -0.08 | -0.11 |
IMTXW Frequently Asked Questions
What is immatics biotechnologies GmbH stock symbol ?
immatics biotechnologies GmbH is a US stock and trading under the symbol IMTXW
What is immatics biotechnologies GmbH stock quote today ?
immatics biotechnologies GmbH stock price is $2.39 today.
Is immatics biotechnologies GmbH stock public?
Yes, immatics biotechnologies GmbH is a publicly traded company.
Company Profile
- Market Capitalization 1.05B
- Employee 432
- CEO Dr. Harpreet Singh Ph.D.
- Headquarters Tübingen,US
- IPO Date 2020-07-02
-
Website
https://www.immatics.com 
Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the discovery and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its products pipeline includes IMA203 that targets solid tumors, which is in Phase 1b clinical trial; IMA203CD8, a cell therapy product that is in Phase 1b clinical trial; IMA204 that targets tumor stroma, which is in preclinical stage; and IMA30x, an allogenic cellular therapy product candidate, which is in preclinical stage. The company also develops TCR Bispecifics products, including IMA401, which is in Phase 1b clinical trial; and IMA402 and IMA403, which are in preclinical stages. The company has a strategic collaboration agreement with MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Corporation to develop novel adoptive cell therapies targeting multiple cancers; and Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications. Immatics N.V. is headquartered in Tübingen, Germany.
